Sonoma Pharmaceuticals Q4 EPS $(0.31) Up From $(1.07) YoY, Sales $3.01M Up From $2.30M YoY
Portfolio Pulse from Bill Haddad
Sonoma Pharmaceuticals reported Q4 losses of $0.31 per share, a 71.03% improvement from last year's $1.07 loss per share. Sales increased by 31.16% to $3.01 million compared to $2.30 million last year.
June 22, 2023 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonoma Pharmaceuticals' Q4 earnings show a significant improvement in losses and sales compared to last year.
Sonoma Pharmaceuticals' Q4 earnings report shows a significant improvement in both losses and sales compared to the same period last year. The reduced losses and increased sales indicate a positive trend for the company, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100